Long-term treatment with golimumab for severe uveitis

Ocular Immunology and Inflammation

Volumn 22, Issue 2, 2014, Pages 90-95

  Miserocchi, Elisabetta ^a   Modorati, Giulio ^a   Pontikaki, Irene ^b   Meroni, Pier Luigi ^b   Gerloni, Valeria ^b  

^a VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^b ISTITUTO ORTOPEDICO GAETANO PINI   (Italy)

Author keywords

Golimumab; HLA B27; JIA; TNF alpha blockers; Uveitis

Indexed keywords

ABATACEPT; ADALIMUMAB; ANTIBIOTIC AGENT; ETANERCEPT; GOLIMUMAB; HLA B27 ANTIGEN; INFLIXIMAB; METHOTREXATE; PREDNISOLONE ACETATE; RITUXIMAB; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL PNEUMONIA; BIOLOGICAL THERAPY; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG ERUPTION; DRUG INDICATION; DRUG SAFETY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HUMAN; JUVENILE RHEUMATOID ARTHRITIS; LONG TERM CARE; LUNG INFECTION; MALE; MIDDLE AGED; OUTCOME ASSESSMENT; RETROSPECTIVE STUDY; SEVERE RECALCITRANT UVEITIS; SKIN MANIFESTATION; SPONDYLOARTHROPATHY; SYSTEMIC THERAPY; TREATMENT RESPONSE; UVEITIS; VISUAL ACUITY; YOUNG ADULT; ADOLESCENT; ANTAGONISTS AND INHIBITORS; AUTOIMMUNE DISEASE; COMPLICATION; DOSE RESPONSE; IMMUNOLOGY; SEVERITY OF ILLNESS INDEX; TIME; TREATMENT OUTCOME;

ADOLESCENT; ADULT; ANTIBODIES, MONOCLONAL; ARTHRITIS, JUVENILE; AUTOIMMUNE DISEASES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLLOW-UP STUDIES; HLA-B27 ANTIGEN; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA; UVEITIS; YOUNG ADULT;

EID: 84897546532     PISSN: 09273948     EISSN: 17445078     Source Type: Journal    
DOI: 10.3109/09273948.2013.844265     Document Type: Article

References (18)

1. Saurenmann RK, Levin AV, Feldman BM, et al. Prevalence, risk factors, and outcome of uveitis in juvenile idiopathic arthritis: A long-Term follow-up study. Arthritis Rheum. 2007;56:647-657
2. Power WJ, Rodriguez A, Peroza-Seres M, Foster CS. Outcomes in anterior uveitis associated with the HLAB27 haplotype. Ophthalmology. 1998;105;1646-1651
3. Miserocchi E, Pontikaki I, Modorati G, et al. Anti-CD 20 monoclonal antibody (rituximab) treatment for inflammatory ocular diseases. Autoimmun Rev. 2011;11:35-39
4. Suhler EB, Smith JR, Wertheim MS, et al. A prospective trial of infliximab therapy for refractory uveitis: Preliminary safety and efficacy outcomes. Arch Ophthalmol. 2005; 123:903-912
5. Saurenmann RK, Levin AV, Rose JB, et al. Tumor necrosis factor alpha inhibitors in the treatment of childhood uveitis. Rheumatology. 2006;45:982-989
6. Foeldvari I, Nielsen S, Kummerle-Deschner J, et al. Tumor necrosis factor-Alpha blocker in treatment of juvenile idiopathic arthritis-Associated uveitis refractory to second-line agents: Results of a multinational survey. J Rheumatol. 2007;34:1146-1150
7. Rudwaleit M, Rodevand E, Holck P, et al. Adalimumab effectively reduces the rate of anterior uveitis flares in patients with active ankylosing spondylitis: Results of a prospective open-label study. Ann Rheum Dis. 2009;68: 696-701
8. Gerloni V, Pontikaki I, Gattinara M, Fantini F. Focus on adverse events of tumour necrosis factor alpha blockade in juvenile idiopathic arthritis in an open monocentric longterm prospective study of 163 patients. Ann Rheum Dis. 2008;67:1145-1152
9. Keystone E, Genovese MC, Klareskog L, et al. Golimumab in patients with active rheumatoid arthritis despite methotrextae therapy: 52-week results of the GOFORWARD study. Ann Rheum Dis. 2010;69:1129-1135
10. Smolen JS, Kay J, Doyle MK, et al. Golimumab in patients with active rheumatoid arthritis after treatment with tumor necrosis factor a inhibitors (GO-AFTER study): A multicentre, randomised, double-blind, placebo-controlled, phase III trial. Lancet. 2009; 374:210-221
11. Emery P, Fleischmann RM, Moreland LW, et al. Golimumab, a human anti-Tumor necrosis factor a monoclonal antibody, injected subcutaneously every four weeks in methotrexate-nai?ve patients with active rheumatoid arthritis: Twenty-four-week results of a phase III, multicenter, randomized, double-blind, placebo-controlled study of golimumab before methotrexate as first-line therapy for early-onset rheumatoid arthritis. Arthritis Rheum. 2009;60:2272-2283
12. Petty RE, Southwood TR, Manners P, et al. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: Second revision, Edmonton, 2001. J Rheumatol. 2004;31:390-392
13. The Standardization of Uveitis Nomenclature (SUN) working group. Standardization of uveitis nomenclature for reporting clinical data: Results of the first international workshop. Am J Ophthalmol. 2005;140:509-516
14. Cordero-Coma M, Salom D, Diaz-Llopis M, et al. Golimumab for uveitis. Ophthalmology. 2011;118:1892
15. William M, Faez S, Papaliodis GN, Lobo AM. Golimumab for the treatment of refractory juvenile idiopathic arthritisassociated uveitis. J Ophthal Inflamm Infect. 2012;2:231-233
16. Mesquida M, Hernandez MV, Llorenc V, et al. Behçet disease-Associated uveitis successfully treated with golimumab. Ocul Immunol Inflamm. 2012;21:160-162
17. Miserocchi E, Modorati G, Pontikaki I, et al. Golimumab treatment for complicated uveitis. Clin Exp Rheumatol. 2013;31:320-321
18. Hyrich KL, Lunt M, Watson KD, et al. Outcomes after switching from one anti-Tumor necrosis factor alpha agent to a second anti-Tumor necrosis factor alpha agent in patients with rheumatoid arthritis: Results from a large UK national cohort study. Arthritis Rheum. 2007;56:13-20